Crispr Therapeutics is trading at $50.09, down 4.32%, amid biotech-sector weakness.
- XBI is down 2.04% during the session, while the Nasdaq Composite is down 1.28%; elevated Treasury yields and oil prices are also weighing on risk sentiment.
- Crispr Therapeutics announced an upcoming November 9 presentation of CTX310 Phase 1b data. The data remain embargoed, so this is not evidence of a negative result or a direct cause of the decline.